statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX Research Report) today and set a price target o...

Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex

Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex PR...

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals...

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon...

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily...

Vertex to Announce Second Quarter 2024 Financial Results on August 1

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a...

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Latest Ratings for VRTX
 DateFirmActionFromTo Feb 2022RBC CapitalDowngradesOutperformSector Perform Jan 2022BMO CapitalUpgradesMarket PerformOutperform Dec 2021Wells FargoInitiates Coverage...

Peering Into Vertex Pharmaceuticals's Recent Short Interest

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy...

13 Analysts Have This To Say About Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Volume	774,126.00
52-Wk High	$503.99
52-Wk Low	$340.20

VRTX Vertex Pharmaceuticals, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals